Clinical Data Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity PharmaTimesLatebreaking EULAR results highlight sustained responses through week 52Immunology & InflammationRead full story pharminent June 4, 2026 (Last updated: June 4, 2026) PharmaTimes Latebreaking EULAR results highlight sustained responses through week 52 Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnershipNext: Alnylam hops on AI train with up to $2B Inceptive partnership Related Stories Clinical Data Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs pharminent July 14, 2026 Clinical Data Major trial launched to explore GLP-1 benefit in dementia pharminent July 13, 2026 Clinical Data GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China pharminent July 10, 2026
